Muscle-Invasive Urothelial Carcinoma of the Bladder

Urology

Volumn 69, Issue 1 SUPPL., 2007, Pages 3-16

  Malkowicz, S Bruce ^a   van Poppel, Hendrik ^b   Mickisch, Gerald ^c   Pansadoro, Vito ^d   Thüroff, Joachim ^e   Soloway, Mark S ^f   Chang, Sam ^g   Benson, Mitchell ^h   Fukui, Iwao ⁱ  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c Centrum für Operative Urologie Bremen   (Germany)

^d Vincenzo Pansadoro Foundation   (Italy)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^h NewYork Presbyterian Hospital   (United States)

ⁱ CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MARKER;

ARTICLE; BLADDER CARCINOMA; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PATHWAY; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; CYSTECTOMY; FEMALE GENITAL SYSTEM; FOLLOW UP; GOLD STANDARD; HUMAN; LAPAROSCOPIC SURGERY; LONG TERM CARE; LYMPH NODE DISSECTION; LYMPHADENECTOMY; OUTCOME ASSESSMENT; PELVIS LYMPH NODE; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE; ROBOTICS; SAFETY; SEMINAL VESICLE; STANDARDIZATION; SURGICAL TECHNIQUE; SURVIVAL RATE; THERAPY EFFECT; TRANSURETHRAL RESECTION; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

EID: 33846635592     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.09.028     Document Type: Review

References (122)

1. Hayne D., Arya M., Quinn M.J., et al. Current trends in bladder cancer in England and Wales. J Urol 172 (2004) 1051-1055
2. Snyder C., Harlan L., Knopf K., et al. Patterns of care for the treatment of bladder cancer. J Urol 169 (2003) 1697-1701
3. Hollenbeck B.K., Miller D.C., Taub D., et al. Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old and older. Urology 64 (2004) 292-297
4. Herr H.W. Routine CT scan in cystectomy patients: does it change management?. Urology 47 (1996) 785-791
5. Haleblian G.E., Skinner E.C., Dickinson M.G., et al. Hydronephrosis as a prognostic indicator in bladder cancer patients. J Urol 160 Pt 1 (1998) 2011-2014
6. Robinson P., Collins C.D., Ryder W.D., et al. Relationship of MRI and clinical staging to outcome in invasive bladder cancer treated by radiotherapy. Clin Radiol 55 (2000) 301-306
7. Braendengen M., Winderen M., and Fossa S.D. Clinical significance of routine pre-cystectomy bone scans in patients with muscle-invasive bladder cancer. Br J Urol 77 (1996) L36-L40
8. Bachor R., Korzerke J., Reske S.N., et al. Lymph node staging of bladder neck carcinoma with positron emission tomography in patients with bladder cancer. Urologe A 38 (1999) 46-50
9. Hara I., Miyake H., Hara S., et al. Optimal timing of radical cystectomy for patients with invasive transitional cell carcinoma of the bladder. Jpn J Clin Oncol 32 (2002) 14-18
10. Sanchez-Ortiz R.F., Huang W.C., Mick R., et al. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 169 (2003) 110-115
11. Chang S.S., Hassan J.M., Cokson M.S., et al. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol 170 Pt 1 (2003) 1085-1087
12. Stroumbakis N., Herr H.W., Cookson M.S., et al. Radical cystectomy in the octogenarian. J Urol 158 (1997) 2113-2117
13. Chang S.S., Alberts G., Cookson M.S., et al. Radical cystectomy is safe in elderly patients at high risk. J Urol 166 (2001) 938-941
14. Figueroa A.J., Stein J.P., Dickinson M., et al. Radical cystectomy for elderly patients with bladder carcinoma: an updated experience with 404 patients. Cancer 83 (1998) 141-147
15. Soulie M., Straub M., Game X., et al. A multicenter study of the morbidity of radical cystectomy in select elderly patients with bladder cancer. J Urol 167 (2002) 1325-1328
16. Lance R.S., Dinney C.P., Swanson D., et al. Radical cystectomy for invasive bladder cancer in the octogenarian. Oncol Rep 8 (2001) 723-726
17. Farnham S.B., Cookson M.S., Alberts G., et al. Benefit of radical cystectomy in the elderly patient with significant co-morbidities. Urol Oncol 22 (2004) 178-181
18. Chahal R., Sundaram S.K., Iddenden R., et al. A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire. Eur Urol 43 (2003) 246-257
19. Miller D.C., Taub D.A., Dunn R.L., et al. The impact of co-morbid disease on cancer control and survival following radical cystectomy. J Urol 169 (2003) 105-109
20. Gheiler E.L., Lovisolo J.A., Tiguert R., et al. Results of a clinical care pathway for radical prostatectomy patients in an open hospital-multiphysician system. Eur Urol 35 (1999) 210-216
21. Klein E.A., Grass J.A., Calabrese D.A., et al. Maintaining quality of care and patient satisfaction with radical prostatectomy in the era of cost containment. Urology 48 (1996) 269-275
22. Koch M.O., Smith Jr. J.A., Hodge E.M., et al. Prospective development of a cost-efficient program for radical retropubic prostatectomy. Urology 44 (1994) 311-318
23. Baumgartner R.G., Wells N., Chang S.S., et al. Causes of increased length of stay following radical cystectomy. Urol Nurs 22 (2002) 319-324
24. Frazier H.A., Robertson J.E., and Paulson D.F. Complications of radical cystectomy and urinary diversion: a retrospective review of 675 cases in 2 decades. J Urol 148 (1992) 1401-1411
25. Montie J.E., and Wood Jr. D.P. The risk of radical cystectomy. Br J Urol 63 (1989) 483-489
26. Rosario D.J., Becker M., and Anderson J.B. The changing pattern of mortality and morbidity from radical cystectomy. BJU Int 85 (2000) 427-434
27. Parekh D.J., Gilbert W.B., Koch M.O., et al. Continent urinary reconstruction versus ileal conduit: a contemporary single-institution comparison of perioperative morbidity and mortality. Urology 55 (2000) 852-857
28. Benson M.C., Slawin K.M., Wechsler M.H., et al. Analysis of continent versus standard urinary diversion. Br J Urol 69 (1992) 156-162
29. Esrig D., Elmajian D., Groshen S., et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331 (1994) 1259-1264
30. Stein J.P., Ginsberg D.A., Grossfeld G.D., et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 90 (1998) 1072-1079
31. Cote R.J., Dunn M.D., Chatterjee S.J., et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 58 (1998) 1090-1094
32. Grossfeld G.D., Ginsberg D.A., Stein J.P., et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 89 (1997) 219-227
33. Byrne R.R., Shariat S.F., Brown R., et al. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol 165 (2001) 1473-1479
34. Matsumoto K., Shariat S.F., Casella R., et al. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol 170 Pt 1 (2003) 2248-2252
35. Shariat S.F., Monoski M.A., Andrews B., et al. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology 61 (2003) 1053-1058
36. Del Pizzo J.J., Borkowski A., Jacobs S.C., et al. Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol 155 (1999) 1129-1136
37. Shariat S.F., Kim J., Nguyen C., et al. Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. Urology 61 (2003) 359-364
38. Shariat S.F., Kim J.H., Ayala G.E., et al. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol 169 (2003) 938-942
39. Zhao H., Grossman H.B., Spitz M.R., et al. Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. J Urol 169 (2003) 714-717
40. Andrews B., Shariat S.F., Kim J.H., et al. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol 167 (2002) 1475-1481
41. Malmstrom P.U., Ren Z.P., Sherif A., et al. Early metastatic progression of bladder carcinoma: molecular profile of primary tumor and sentinel lymph node. J Urol 168 (2002) 2240-2244
42. Garcia del Muro X., Condom E., Vigues F., et al. p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer 100 (2004) 1859-1867
43. Agerbaek M., Alsner J., Marcussen N., et al. Retinoblastoma protein expression is an independent predictor of both radiation response and survival in muscle-invasive bladder cancer. Br J Cancer 89 (2003) 298-304
44. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19 (2001) l666-l1675
45. Dalbagni G., Genega E., Hashibe M., et al. Cystectomy for bladder cancer: a contemporary series. J Urol 165 (2001) 1111-1116
46. Quek M.L., Stein J.P., Clark P.E., et al. Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer 98 (2003) 955-961
47. Takahashi A., Tsukamoto T., Tobisu K., et al. Radical cystectomy for invasive bladder cancer: results of multi-institutional pooled analysis. Jpn J Clin Oncol 34 (2004) 14-19
48. Madersbacher S., Hochreiter W., Burkhard F., et al. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 21 (2003) 690-696
49. Ghoneim M.A., el-Mekresh M.M., el-Baz M.A., et al. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J Urol 158 (1997) 393-399
50. Lee K.L., Freiha F., Presti Jr. J.C., et al. Gender difference in radical cystectomy: complications and blood loss. Urology 63 (2004) 1095-1099
51. Chang S.S., Smith Jr. J.A., and Cookson M.S. Decreasing blood loss in patients treated with radical cystectomy: a prospective randomized trial using a new stapling device. J Urol 169 (2002) 951-954
52. Abrams P, Grant A, Khoury S. Evidence-based medicine: overview of the main steps for developing and grading guideline recommendations. In Abrams P, Cardozo L, Khoury S, et al (Eds), Incontinence, Volume 1. Plymouth, United Kingdom, Health Publications Ltd., pp 10-11
53. Bochner B.H., Figueroa A.J., Skinner E.C., et al. Salvage radical cystoprostatectomy and orthotopic urinary diversion following radiation failure. J Urol 160 (1998) 29-33
54. Schuster T.G., Marcovich R., Sheffield J., et al. Radical cystectomy for bladder cancer after definitive prostate cancer treatment. Urology 61 (2003) 342-347 discussion 347
55. Herr H.W., and Donat S.M. Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy. J Urol 165 (2001) 62-64 discussion 64
56. Miller R.S., Freiha F.S., Reese J.H., et al. Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. J Urol 150 (1993) 65-69
57. Dodd P.M., McCaffrey J.A., Herr H., et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol 17 (1999) 2546-2552
58. Siefker-Radtke A.O., Walsh G.L., Pisters L.L., et al. Is there a role for surgery in the management of metastatic urothelial cancer?. The M. D. Anderson experience. J Urol 171 (2004) 145-148
59. Herr H.W. Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy. Urology 61 (2003) 105-108
60. Herr H., Lee C., Chang S., et al. Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collaborative group report. J Urol 171 (2004) 1823-1828
61. Herr H.W., Faulkner J.R., Grossman H.B., et al. Pathologic evaluation of radical cystectomy specimens: a cooperative group report. Cancer 100 (2004) 2470-2475
62. Herr H.W., Faulkner J.R., Grossman H.B., et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol 22 (2004) 2781-2789
63. Harisinghani M.G., Dixon W.T., Saksena M.A., et al. MR lymphangiography: imaging strategies to optimize the imaging of lymph nodes with ferumoxtran-10. Radiographics 24 (2004) 867-878
64. Leissner J., Hohenfellner R., Thuroff J.W., et al. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder: significance for staging and prognosis. BJU Int 85 (2000) 817-823
65. Mills R.D., Turner W.H., Fleischmann A., et al. Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy. J Urol 166 (2001) 19-23
66. Liedberg F., Chebil G., Davidsson T., et al. Bladder cancer and the sentinel node concept. Aktuelle Urol 34 (2003) 115-118
67. Konety B.R., and Joslyn S.A. Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. J Urol 170 (2003) 1765-1771
68. Poulsen A., Horn T., and Steven K. Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J Urol 160 (1998) 2015-2019
69. Herr H.W. Superiority of ratio based lymph node staging for bladder cancer. J Urol 169 (2003) 943-945
70. Vieweg J., Gschwend J.E., Herr H.W., et al. The impact of primary stage on survival in patients with lymph node positive bladder cancer. J Urol 161 (1999) 72-76
71. Vieweg J., Gschwend J.E., Herr H., et al. Pelvic lymph node dissection can be curative in patients with lymph node positive disease. J Urol 161 (1999) 449-454
72. Leissner J., Ghoneim H., Abol-Enein J., et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol 171 (2004) 139-144
73. Lerner S.P., Skinner D.G., Lieskovsky G., et al. The rationale for en bloc PLND for bladder cancer patients with nodal metastases: long-term results. J Urol 149 (1993) 758-764
74. Herr H.W. Surgical factors in bladder cancer: more (nodes) + more (pathology) = less (mortality). BJU Int 92 (2003) 187-188
75. Bochner B.H., Herr H.W., and Reuter V.E. Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens. J Urol 166 (2001) 2295-2296
76. Konety B.R., Joslyn S.A., and O'Donnell M. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnoses with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. J Urol 169 (2003) 946-950
77. Silver D.A., Stoumbakis N., Russo P., et al. Ureteral carcinoma in situ at radical csytectomy: does the margin matter?. J Urol 158 (1997) 768-771
78. Schoenberg M.P., Carter H.B., and Epstein J.I. Ureteral frozen section analysis during cystectomy: a reassessment. J Urol 155 (1996) 1218-1220
79. Johnson D.E., Wishnow K.I., and Tenney D. Are frozen-section examinations of ureteral margins required for all patients undergoing radical cystectomy for bladder cancer?. Urology 33 (1989) 451-454
80. Kenworthy P., Tanguay S., and Dinney C.P. The risk of upper tract recurrence following cystectomy in patients with transitional cell carcinoma involving the distal ureter. J Urol 155 (1996) 504-505
81. Huang W., Sanchez-Ortiz R.F., Genega E.M., et al. The significance of frozen section ureteral abnormalities at the time of cystectomy. [abstract]. J Urol 171 (2004) 67
82. Schlegel P.N., and Walsh P.C. Neuroanatomical approach to radical cystoprostatectomy with preservation of sexual function. J Urol 38 (1987) 1402
83. Daneshmand S., Stein J.P., Lessner T.J., et al. Prognosis of seminal vesicle involvement by transitional cell carcinoma of the bladder. J Urol 172 (2004) 81-84
84. Volkmer B.G., Kufer R., Maier S., et al. Outcome in patients with seminal vesicle invasion after radical cystectomy. J Urol 169 (2003) 1299-1302
85. Muto G., and Moroni M. Seminal-sparing cystectomy and ileocapsuloplasty. [in Italian]. Acta Urologica Italica 12 (1998) 47-50
86. Muto G., Bardari F., D'urso L., et al. Seminal sparing cystectomy and ileocapsuloplasty: long-term follow-up results. J Urol 172 (2004) 76-80
87. Horenblas S., Meinhardt W., Ijzerman W., et al. Sexuality preserving cystectomy and neobladder: initial results. J Urol 166 (2001) 837-840
88. Vallancien G., Fettouh H.A.E., Cathelineau X., et al. Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. J Urol 168 (2002) 2413-2417
89. Fang-Jian Z., Zi-Ke Q., Hui H., et al. Radical cystectomy with sparing partial prostate for invasive bladder cancer. Chin J Cancer 22 (2004) 1066-1069
90. Saidi A., Nahon O., Daniel L., et al. Prostate-sparing cystectomy: long term functional and oncological results. Prog Urol 14 (2004) 172-177
91. Colombo R., Bertini R., Salonia A., et al. Overall clinical outcomes after nerve and seminal sparing radical cystectomy for the treatment of organ confined bladder cancer. J Urol 171 (2004) 1819-1822
92. Stein J.P., Esrig D., Freeman J.A., et al. Prospective pathologic analysis of female cystectomy specimens: risk factors for orthotopic diversion in women. Urology 51 (1998) 951-957
93. Ghoneim M.A. Surgical atlas: orthotopic bladder substitution in women after cystectomy for bladder cancer. BJU Int 93 (2004) 891-899
94. Ali-el-Dein B., Abdel-Latif M., Ashamallah A., et al. Local urethral recurrence after radical cystectomy and orthotopic bladder substitution in women: a prospective study. J Urol 171 (2004) 275-281
95. Chang S.S., Cole E., Cookson M.S., et al. Preservation of the anterior vaginal wall during female radical cystectomy with orthotopic urinary diversion: technique and results. J Urol 168 (2002) 1442-1446
96. Ali-el-Dein B., el-Sobky E., Hohenfellner M., et al. Orthotopic bladder substitution in women: functional evaluation. J Urol 161 (1999) 1875-1881
97. Blute M.L., and Gburek B.M. Continent orthotopic urinary diversion in female patients: early Mayo Clinic experience. Mayo Clin Proc 73 (1998) 501-509
98. Mills R.D., and Studer U.E. Female orthotopic bladder substitution: a good operation in the right circumstances. J Urol 163 (2000) 1501-1507
99. Ghoneim M.A. Orthotopic bladder substitution in women following cystectomy for bladder cancer. Urol Clin North Am 24 (1997) 225-236
100. Chang S.S., Cole E., Smith Jr. J.A., et al. Pathological findings of gynecologic organs obtained at female radical cystectomy. J Urol 168 (2002) 147
101. Ali-El-Dein B., Abdel-Latif M., Mosbah A., et al. Secondary malignant involvement of gynecologic organs in radical cystectomy specimens in women: is it mandatory to remove these organs routinely?. J Urol 172 (2004) 885-887
102. Stenzl A., Draxl H., Posch B., et al. The risk of urethral tumors in female bladder cancer: can the urethra be used for orthotopic reconstruction of the lower urinary tract?. J Urol 153 (1999) 950-958
103. Akerlund S., Delin K., Kock N.G., et al. Renal function and upper urinary tract configuration following urinary diversion to a continent ileal reservoir (Kock pouch): a prospective 5 to 11-year followup after reservoir construction. J Urol 142 (1989) 964-968
104. Stein J.P., Clark P., Miranda G., et al. Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients. J Urol 173 (2005) 1163-1168
105. Bochner B.H., Montie J.E., and Lee C.T. Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer. Urol Clin North Am 30 (2003) 777-789
106. Cummings K.B., Mason J.T., Correa Jr. R.J., et al. Segmental resection in the management of bladder carcinoma. J Urol 119 (1978) 56-62
107. Novick A.C., and Stewart B.H. Partial cystectomy in the treatment of primary and secondary carcinoma of the bladder. J Urol 116 (1976) 570-575
108. Sweeney P., Kursh E.D., and Resnick M.I. Partial cystectomy. Urol Clin North Am 19 (1992) 701-711
109. Kaneti J. Partial cystectomy in the management of bladder carcinoma. Eur Urol 12 (1986) 249-257
110. Holzbeierlein J.M., Lopez-Corona E., Bochner B.H., et al. Partial cystectomy: a contemporary review of the MSKCC experience and recommendations for patient selection. J Urol 172 (2004) 878-881
111. Golijanin D., Yossepowitch O., Beck S.D., et al. Carcinoma in a bladder diverticulum: presentation and treatment outcome. J Urol 170 (2003) 1761-1764
112. Sternberg C.N., Pansadoro V., Calabro F., et al. Can patient selection for bladder preservation be based on response to chemotherapy?. Cancer 97 (2003) 1644-1652
113. Herr H.W., Bajorin D.F., and Scher H.I. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 16 (1998) 1298-1301
114. Barnes R.W., Dick A.L., Hadley H.L., et al. Survival following transurethral resection of bladder carcinoma. Cancer Res 37 Pt 2 (1977) 2895-2897
115. Henry K., Miller J., Mori M., et al. Comparison of transurethral resection to radical therapies for stage B bladder tumors. J Urol 140 (1988) 964-967
116. Lee S.E., Jeong I.G., Ku J.H., et al. Impact of transurethral resection of bladder tumor: analysis of cystectomy specimens to evaluate for residual tumor. Urology 63 (2004) 873-877 discussion, 877
117. Bayraktar Z., Gurbuz G., Tasci A.I., et al. Staging error in the bladder tumor: the correlation between stage of TUR and cystectomy. Int Urol Nephrol 33 (2001) 627-629
118. Roosen J.U., Geertsen U., Jahn H., et al. Invasive, high grade transitional cell carcinoma of the bladder treated with transurethral resection: a survival analysis focusing on TUR as monotherapy. Scand J Urol Nephrol 31 (1997) 39-42
119. O'Flynn J.D., Smith J.M., and Hanson J.S. Transurethral resection for the assessment and treatment of vesical neoplasms: a review of 840 consecutive cases. Eur Urol 1 (1975) 38-40
120. Thomas D.J., Roberts J.T., Hall R.R., et al. Radical transurethral resection and chemotherapy in the treatment of muscle-invasive bladder cancer: a long-term follow-up. BJU Int 83 (1999) 432-437
121. Herr H.W. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 19 (2001) 89-93
122. Solsona E., Iborra I., Ricos J.V., et al. Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: long-term followup of a prospective study. J Urol 159 (1998) 95-98 discussion, 98-99